MRD Assessment Improves PFS Prediction for Patients With CLL

Share this content:
Minimal residual disease assessment improves prediction of progression-free survival for patients with chronic lymphocytic leukemia.
Minimal residual disease assessment improves prediction of progression-free survival for patients with chronic lymphocytic leukemia.

Minimal residual disease (MRD) assessment improves prediction of progression-free survival for patients with chronic lymphocytic leukemia (CLL) who achieve a complete remission or partial response, according to a study published in the Journal of Clinical Oncology.1

MRD refers to the leukemic cells that persist during treatment or while the patient is in remission, and explains why many patients relapse. The value of MRD for predicting clinical outcome, however, is unclear.

Investigators analyzed MRD and clinical response data from 554 patients with CLL treated with chemotherapy, with or without rituximab, who were included in 2 randomized phase 3 trials.

Patients with MRD-negative complete remission, MRD-negative partial response, MRD-positive complete remission, and MRD-positive partial response had a median progression-free survival of 61 months, 54 months, 35 months, and 21 months, respectively.

There was no significant difference in progression-free survival among patients with MRD-negative complete remission and those with MRD-negative partial response. In contrast, progression-free survival was significantly longer for patients with MRD-negative partial response, compared with those with MRD-positive complete remission.

RELATED: Poor Sleep Quality Associated With Symptom Burden Among Phase 1 Trial Participants

Researchers also found that, unlike persisting lymphadenopathy, residual splenomegaly does not affect progression-free survival among patients with MRD-negative partial response.                  

Reference

  1. Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: Comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016 Aug 29. doi: 10.1200/JCO.2016.67.1305 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters